Background: Artificial intelligence in medicine has largely relied on supervised training of disease-specific models, limiting scalability in conditions where labeled data are scarce. Large language models (LLMs), which encode broad medical knowledge through large-scale pretraining, offer an alternative paradigm in which structured physiological measurements can be interpreted directly without task-specific model training. Objective: To evaluate whether smartphone-derived ocular motor biomarkers can be translated into clinically meaningful probabilistic assessments of Huntington’s disease (HD) using general-purpose LLMs operating as inference engines. Methods: In this prospective proof-of-concept study, 26 participants (13 with genetically confirmed HD and 13 age-matched controls) completed a standardized ocular motor assessment using a custom smartphone application. Quantitative eye-movement metrics were validated against expert neurologist ratings. Structured physiological features were then provided to four general-purpose LLMs without task-specific training or diagnostic labels, and the models generated an AI-Assigned HD Probability Score (HAIPS). Discriminative performance and associations with clinical severity measures were evaluated. Results: Smartphone-derived ocular motor metrics showed strong agreement with clinician assessments (Spearman ρ = 0.76–0.95; all p < 0.001), confirming preservation of clinically meaningful physiological signals. LLM-derived HAIPS distinguished HD from controls with high accuracy (AUC 0.879–0.944), with no significant differences across models. Discrimination was statistically equivalent to a supervised logistic regression model trained on the same features. HAIPS correlated strongly with established measures of disease severity, including cognitive (MoCA, ρ = −0.86), functional (TFC, ρ = −0.74), and motor impairment (UHDRS, ρ = 0.85) (all p ≤ 0.003). Conclusions: Structured ocular motor biomarkers acquired using a consumer smartphone can be translated into clinically meaningful probabilistic assessments of HD by general-purpose LLMs without disease-specific model training. These findings support a framework in which physiologically grounded digital biomarkers are coupled with general-purpose inference models, potentially enabling scalable assessment in rare neurological diseases where labeled data are limited.
Huntington's disease (HD) is a rare, autosomal dominant neurodegenerative disorder caused by a pathogenic CAG expansion in the huntingtin gene, classically characterized by a triad of cognitive, psychiatric, and motor symptoms. Involuntary movements known as chorea are the most notable feature of HD. Despite the negative impact chorea can have on many aspects of day-to-day life, pharmacologic treatment remains underutilized in clinical practice. Barriers include anosognosia, a complex treatment landscape, limited evidence-based guidelines, and variable access to care. In February 2025, 11 North American HD specialists and members of the Huntington Study Group (HSG) Motor Treatment Task Force, who collectively care for ∼1500 people with HD (PwHD) convened to discuss current practices and challenges in the pharmacologic treatment of chorea. Insights were supplemented by responses to a long-form questionnaire distributed via email. Attendees and respondents described practical approaches to assessing chorea, engaging care partners, and setting goal-oriented treatment plans. This review draws on collective experience to highlight practical, real-world strategies for the evaluation and treatment of HD chorea. The two most common medication classes used to suppress chorea are vesicular monoamine transporter 2 (VMAT2) inhibitors and antipsychotics. Individualized titration, regular patient and care partner feedback, and functional, rather than purely motor-based, assessments are key to optimizing therapy. By integrating pharmacologic therapy with multidisciplinary care and holistic, goal-oriented communication about the impact of chorea, clinicians can meaningfully improve safety, independence, and quality of life for individuals and families affected by HD.